A Comparative study about the effectiveness of Ilprazole in refractory GERD according to dosing method

Hanyang University Seoul Hospital0 个研究点目标入组 164 人开始时间: 待定最近更新: 2019年4月23日

适应症

试验速览

暂无简介。

•(1)Patient with refractory Gastroesophageal reflux disease who remained symptomatic in spite of standard therapy of current Proton Pump Inhibitor except Ilaprazole
•(2)Those who heard the explanation of this clinical trial and decided to voluntarily participate and signed the consent form

•(1) Those with hypersensitivity to Proton pump inhibitor including Ilaprazole
•(2) Those who were not benefited from other Proton pump inhibitor administration for Gastroesophageal reflux disease due to low compliance.
•(3) Those with need to constantly take Steroids or Non steroidal anti inflammatory drugs including Aspirin (more than 325mg/d), Warfarin, Coumarin.
•(4) Those with Esophageal stricture, 3 cm of Barrett's esophagus, gastrointestinal bleeding, stomach and duodenal ulcer, Zollinger-Ellison syndrome, malignant tumor or other serious disease.
•(5) Those who had been treated with Helicobacter pylori eradication therapy within 6 months before participation of the clinical trial.
•(6) Those who has undergone gastric acid suppression surgery or gastro-duodenal surgery.
•(7) Those who has undergone major surgery affecting gastric acid secretion except surgery such as appendectomy, cholecystectomy, hysterectomy.
•(8) Current alcohol addictor or those with the history of drug abuse.
•(9) Pregnant and lactating women
•(10) Childbearing women (Menopausal women who are amenorrheic for at least 12 months are considered to be non-childbearing women)
•(11) Those who participated in other clinical trial within 30 days before Screening.
•(12) Those who are judged to be improper for this clinical trial.

发起方

Hanyang University Seoul Hospital